MRNA closed the week at $203.46, up 11% in five sessions, and the key question has shifted from whether the short squeeze is over to whether the stock can hold gains that the entire analyst community says are unjustified.
The short position continues to unwind at a pace that would have looked impossible in August. Short interest has fallen 17.5% over the past week alone, from roughly 35.7 million shares to 29.4 million, and is down 39% over the past month. As recently as late August, shorts held more than 51 million shares. They now hold fewer than 30 million, equivalent to 7.5% of the free float, still a meaningful level but one that is shrinking steadily in both absolute and float-adjusted terms. Borrow conditions confirm there is no structural friction left: availability has climbed to 927%, meaning roughly nine shares are available to borrow for every one already lent out, the loosest the lending pool has been all year. Cost to borrow is down to 0.42%, well below where it was even a month ago. Shorts who want to cover face no obstacles, and the data says many of them are taking that exit. Options positioning has normalised further. The put/call ratio eased to 1.13 on Tuesday, just fractionally above its 20-day average of 1.11 and near the bottom end of the past year's defensive readings. The hedging premium that characterised August has largely evaporated.
The Street is a different picture entirely. The analyst community is fracturing rather than converging around the new price level. Citigroup's Geoff Meacham cut to Sell today, raising his target to $80 from $60, implying 61% downside from current levels. That follows a Rothschild downgrade to Sell on September 3, also with an $81 target. JP Morgan holds an Underweight at $77. Morgan Stanley sits at Equal-Weight with an $89 target. The consensus price target is $120.67, less than 60% of where the stock is trading. Against that, Argus Research upgraded to Buy at the end of August with a $180 target, and UBS lifted its target to $150. The disagreement is genuine and widening. Price-to-book has moved from roughly 11.8 to 17.6 over the past month as the share price ran 47%. The trailing P/E is deeply negative. Bulls point to the ESMO melanoma data and the mRNA platform's expanding pipeline across oncology and cardiovascular disease. Bears point to an unprofitable company trading at a widening premium to almost every measure the Street uses to anchor valuation. The forward EPS growth factor scores in the 89th percentile, suggesting the market is pricing in a material recovery in earnings, but the 90-day EPS momentum rank of 18 says revisions have not followed.
Insider activity over the past few weeks adds texture but not a clear directional signal. President Stephen Hoge sold roughly 80,500 shares across September 14 and 15 at prices between $144 and $147, a combined value of around $11.7 million, both transactions under pre-arranged 10b5-1 plans. CFO James Mock exercised and sold shares on September 10, also under a 10b5-1 plan, netting around $4.7 million from sales at $134.49. The net insider position over the past 90 days is negative, roughly $49 million in net value sold. The planned-sale caveat matters here: these are not discretionary decisions to exit ahead of bad news, they are scheduled liquidations. But the timing, at prices well below where the stock now trades, means insiders were selling into a rally that still had significant room to run, which is at minimum a reminder that even those closest to the company were not positioning for $200-plus in mid-September.
On the ownership register, FMR (Fidelity) remains the largest holder with 13% of shares, and raised its stake from 10.6% to 13.1% as last filed in August. Capital World Investors crossed the 5% threshold with a new 13G filed in August at 5.6%. T. Rowe Price added nearly 4.9 million shares in the most recent reported period. The direction of institutional flow is constructive, with active managers adding rather than trimming, even as the stock was already in the midst of a large move higher. No 13D activist is on the register.
Moderna's next earnings event is November 5. The last two prints produced a 5.2% one-day gain and a 4.8% one-day decline respectively, modest moves relative to the intraday volatility the stock now regularly produces. With short interest still at 7.5% of float and the stock up nearly 50% in a month, the November print will be less about the short position mechanics and more about whether the clinical data from ESMO translates into any revision to the revenue trajectory that bulls need to justify the current multiple.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
